This registration describes the protocol of the currently ongoing systematic review and meta-
analysis aiming to use individual patient data (IPD) from all available randomized clinical …

Background Dexamethasone and remdesivir have the potential to reduce coronavirus
disease 2019 (COVID)–related mortality or recovery time, but their cost-effectiveness in …

FDA Approval of Remdesivir On October 22, 2020, on the basis of the results of three phase
3 clinical trials, the FDA approved remdesivir for use in adults and pediatric patients (12 …

Abstract Background Coronavirus disease 2019 (COVID-19), caused by the novel
coronavirus SARS-CoV-2, has led to significant global mortality and morbidity. Until now, no …

MURGADELLA-SANCHO, Anna et al. Experience in the use of remdesivir in patients with
SARS-CoV-2 pneumonia. Farm Hosp.[online]. 2021, vol. 45, n. 5, pp. 253-257. Epub 16-Ene …

Introduction: Remdesivir was the only antiviral used in the treatment of COVID-19 in the first
wave of the COVID-19 pandemic, following the adaptive COVID-19 treatment trial-1 interim …

Abstract Background and Objectives Remdesivir is an antiviral agent, which was shown to
be safe and effective in treating early COVID-19, but its favourable impact in hospitalised …

Background Evidence has emerged showing potential benefit of Remdesivir and
dexamethasone in severe coronavirus disease 2019 (COVID-19) but results from large …

Objectives We performed a systematic review and network meta-analysis of randomized
controlled trials (RCTs) to provide updated information regarding the clinical efficacy of …

Background: Remdesivir is a broad-spectrum antiviral drug that received emergency use
authorization in the first wave of the COVID-19 pandemic. However, its effectiveness in …